# OnCo record flumatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/flumatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "flumatinib" ;
  schema:name "Flumatinib"@en ;
  schema:alternateName "Xinfu"@en ;
  schema:description "Flumatinib is Hansoh Pharma's second-generation BCR-ABL inhibitor, approved in China in 2019 for newly diagnosed chronic-phase chronic myeloid leukaemia."@en ;
  schema:url <https://onco.cc/drugs/flumatinib/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=flumatinib> ;
  onco:status "approved" ;
  onco:tag "china", "nmpa-approved" ;
  onco:modality "Oral second-generation BCR-ABL tyrosine kinase inhibitor" ;
  onco:approval "CN 2019: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia, chronic phase" ;
  onco:cancers <https://onco.cc/cancers/cml/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/bcr-abl/> ;
  onco:companies <https://onco.cc/companies/hansoh-pharma/> ;
  onco:trials <https://onco.cc/trials/nct04375683/>, <https://onco.cc/trials/nct01503502/>, <https://onco.cc/trials/nct05433532/> .